Nabriva Therapeutics Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Nabriva Therapeutics's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Nabriva Therapeutics to effect 1-for-25 reverse stock split
Sep 15Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta
Jul 18Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022
Apr 04
Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts
Aug 11We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation
Jul 22Nabriva Therapeutics plc 2021 Q1 - Results - Earnings Call Presentation
May 08When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?
Feb 16Nabriva Therapeutics announces proposed public offering
Dec 10Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China
Dec 07Nabriva Therapeutics plc 2020 Q3 - Results - Earnings Call Presentation
Nov 08Revenue & Expenses Breakdown
How Nabriva Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 30 | -55 | 31 | 0 |
| 31 Mar 23 | 37 | -54 | 37 | 0 |
| 31 Dec 22 | 37 | -57 | 45 | 0 |
| 30 Sep 22 | 36 | -47 | 50 | 0 |
| 30 Jun 22 | 35 | -47 | 50 | 0 |
| 31 Mar 22 | 34 | -47 | 52 | 0 |
| 31 Dec 21 | 29 | -49 | 52 | 0 |
| 30 Sep 21 | 22 | -54 | 55 | 0 |
| 30 Jun 21 | 15 | -57 | 53 | 0 |
| 31 Mar 21 | 7 | -60 | 51 | 0 |
| 31 Dec 20 | 5 | -69 | 55 | 0 |
| 30 Sep 20 | 3 | -75 | 55 | 0 |
| 30 Jun 20 | 9 | -80 | 62 | 0 |
| 31 Mar 20 | 9 | -86 | 65 | 0 |
| 31 Dec 19 | 9 | -83 | 62 | 0 |
| 30 Sep 19 | 10 | -91 | 56 | 0 |
| 30 Jun 19 | 3 | -126 | 50 | 0 |
| 31 Mar 19 | 4 | -122 | 45 | 0 |
| 31 Dec 18 | 10 | -115 | 42 | 0 |
| 30 Sep 18 | 10 | -106 | 42 | 0 |
| 30 Jun 18 | 11 | -76 | 39 | 0 |
| 31 Mar 18 | 11 | -72 | 35 | 0 |
| 31 Dec 17 | 5 | -74 | 29 | 0 |
| 30 Sep 17 | 7 | -67 | 23 | 0 |
| 30 Jun 17 | 6 | -59 | 17 | 0 |
| 31 Mar 17 | 7 | -57 | 15 | 0 |
| 31 Dec 16 | 6 | -55 | 14 | 0 |
| 30 Sep 16 | 5 | -67 | 13 | -15 |
| 30 Jun 16 | 5 | -61 | 12 | -8 |
| 31 Mar 16 | 5 | -55 | 10 | -3 |
| 31 Dec 15 | 4 | -51 | 8 | 0 |
| 30 Sep 15 | 3 | -30 | 6 | 18 |
| 30 Jun 15 | 2 | -26 | 5 | 12 |
| 31 Mar 15 | 2 | -21 | 3 | 8 |
| 31 Dec 14 | 2 | -14 | 4 | 0 |
Quality Earnings: Insufficient data to determine if NBRV.F has high quality earnings.
Growing Profit Margin: Insufficient data to determine if NBRV.F's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NBRV.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare NBRV.F's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if NBRV.F's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: NBRV.F has a negative Return on Equity (0%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 12:43 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nabriva Therapeutics plc is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Chiara Russo | Cantor Fitzgerald & Co. |
| Kevin Kedra | G. Research, LLC |